Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

Clinical trial NCT04061863 · UNKNOWN

Trial details

NCT number: NCT04061863
Sponsor: Seoul National University Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2019-08-01
Primary completion: 2022-04-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.